 Mbendazole disrupts Dromel desmoplasia and tumor genesis in two models of pancreatic cancer. Researchers are examining new strategies to improve the poor five-year survival rate of patients with pancreatic cancer. In this trending paper published by Elka Target in 2021, researchers repurposed a drug originally used to destroy parasitic worms and examined its efficacy in treating pancreatic cancer. Read this study and more peer-reviewed oncology-focused research published by Elka Target at ElkaTarget.com